Dr. Brigitte Poirier is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and a clinical professor at Laval University School of Medicine. Dr. Poirier is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada, offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life, despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Canada G1S 4L8
Data not available
Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in QuebecJournal Article
Oncologist, 27 (10), 2022.
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trialJournal Article
Mol Oncol, 16 (12), 2022.
Do Preoperative Prophylactic Antibiotics Reduce Surgical Site Infection Following Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical TrialJournal Article
Ann Surg Oncol, 29 (4), 2022.
A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene StudyJournal Article
Cancers (Basel), 13 (11), 2021.
Estrogens and Glucocorticoids in Mammary Adipose Tissue: Relationships with Body Mass Index and Breast Cancer FeaturesJournal Article
J Clin Endocrinol Metab, 105 (4), 2020.
A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancerJournal Article
Curr Oncol, 26 (1), 2019.
Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC StudyJournal Article
Ann Surg Oncol, 26 (13), 2019.
Simultaneous quantification of estrogens and glucocorticoids in human adipose tissue by liquid-chromatography-tandem mass spectrometryJournal Article
J Steroid Biochem Mol Biol, 195 , 2019.
In response to: Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbiditiesJournal Article
J Surg Oncol, 117 (7), 2018.
Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breastJournal Article
J Surg Oncol, 117 (6), 2018.
- NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
Recently finished projects
- MA-12: Étude randomisée à double insu visant à comparer le tamoxifène avec un placebo chez les patientes atteintes d'un cancer du sein étendu aux ganglions lymphatiques et qui ont complété une chimiothérapie adjuvante ..., from 1997-04-01 to 2021-03-31